# RIBOLARIS: HCP commentary report

> 139 verified statements (17 from clinicians verified by NPI or staff page) from 31 commentary sources · 10 findings · updated Oct 30, 2026

## Report

- Trial: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
- NCT ID: NCT05296746
- Registry: https://clinicaltrials.gov/study/NCT05296746
- Sponsor: SOLTI Breast Cancer Research Group
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: ribociclib
- Indication: clinically high-risk stage II ER+/HER2- breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: 527664bb4f5dd36bf9186b2ff479669319dbc54ac212c18dc6cf9fcaddf73a5c

## Counts

- HCP commentary sources screened: 45
- Sources cited by verified statements: 32
- Verified statements: 139
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 17
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 26
- Voices cited: 25
- Cited voices identity-verified: 18
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

RIBOLARIS asks whether response to neoadjuvant ribociclib plus endocrine therapy can guide chemotherapy omission for patients with clinically high-risk stage II HR-positive/HER2-negative breast cancer. A LinkedIn poster welcomes the study and keeps response-guided omission conditional. In a LinkedIn post, eligibility and historical comparisons are questioned. Long-term clinical validation remains open in the welcoming poster's assessment. The sources reviewed for this edition place RIBOLARIS's preliminary interim-analysis results at ESMO 2025.

## Open Medical Affairs question

What long-term disease control and patient-valued trade-offs would justify chemotherapy omission in this response-defined population?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. An encouraging molecular response is not yet evidence that chemotherapy can safely be omitted
- F2. Eligibility and the historical benchmark are a specific methodological challenge
- F3. Dynamic genomic selection appeals, but assay comparability and response meaning remain open
- F4. Earlier trials motivate chemotherapy replacement; adjuvant add-on evidence does not establish it
- F5. Interest in selective clinical use is accompanied by explicit nonstandard-care boundaries
- F6. Perceived tolerability advantages coexist with substantial hematologic and hepatic toxicity
- F7. Overall survival, duration, cost and cumulative treatment burden remain linked questions
- F8. ctDNA-guided de-escalation is attractive but not yet actionable; nonresponder combinations have safety constraints
- F9. Rapid engagement is interpreted as demand for de-escalation, not measured patient preference
- F10. A separate thread contains consequential but unsubstantiated allegations of harmful intent

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 12 | 13 | 13 | 10 | recorded | 3 |
| F2 | 10 | 8 | 5 | 2 | recorded | 3 |
| F3 | 11 | 10 | 8 | 8 | recorded | 3 |
| F4 | 13 | 10 | 10 | 6 | none recorded | 3 |
| F5 | 11 | 12 | 8 | 7 | recorded | 3 |
| F6 | 12 | 14 | 9 | 7 | recorded | 2 |
| F7 | 7 | 7 | 1 | 3 | none recorded | 3 |
| F8 | 7 | 8 | 2 | 4 | none recorded | 2 |
| F9 | 15 | 13 | 9 | 7 | none recorded | 3 |
| F10 | 2 | 2 | 1 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 8 | 0 | 0 | 0 | 4 | 14 | 0 | 12 posts and articles, 1 podcast or video | yes |
| F2 | 2 | 4 | 0 | 1 | 3 | 10 | 1 | 1 post or article, 3 podcasts and video, 1 publication | yes |
| F3 | 3 | 3 | 1 | 1 | 3 | 13 | 0 | 6 posts and articles, 2 podcasts and video | yes |
| F4 | 6 | 1 | 1 | 4 | 1 | 13 | 1 | 7 posts and articles, 3 podcasts and video | yes |
| F5 | 8 | 1 | 0 | 0 | 2 | 12 | 0 | 6 posts and articles, 1 podcast or video, 1 publication | yes |
| F6 | 8 | 1 | 0 | 0 | 3 | 14 | 0 | 6 posts and articles, 2 podcasts and video, 1 publication | yes |
| F7 | 3 | 3 | 0 | 1 | 0 | 7 | 0 | 1 post or article | yes |
| F8 | 4 | 2 | 0 | 0 | 1 | 7 | 2 | 2 posts and articles | yes |
| F9 | 8 | 3 | 3 | 0 | 1 | 16 | 0 | 6 posts and articles, 2 podcasts and video, 1 publication | yes |
| F10 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 post or article | yes |

### Trial dimensions

- Primary endpoint: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort): F1 (3 shared claims), F2 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F9 (1 shared claims)
- Secondary endpoints: F1 (8 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims), F6 (4 shared claims)
- Population and setting: F1 (1 shared claims), F2 (4 shared claims), F5 (4 shared claims), F6 (1 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims), F4 (3 shared claims), F5 (2 shared claims)
- Safety and tolerability: F1 (3 shared claims), F6 (10 shared claims), F8 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (3 shared claims), F4 (2 shared claims), F5 (3 shared claims), F9 (5 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Eligibility and the historical benchmark are a specific methodological challenge

A LinkedIn poster asked how trial eligibility aligns with the population used for the historical MINDACT comparison.

Source: LinkedIn post, 2025-10-21.

### F3. Dynamic genomic selection appeals, but assay comparability and response meaning remain open

An X poster asked how PAM50 ROR's prognostic performance compares with MammaPrint and Oncotype.

Source: X thread, 2022-04-22.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 139 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 32 | Counts free |
| Speaker attribution for cited voices | 25 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort) | discussed | 13 | 8 |
| Secondary endpoints | discussed | 17 | 15 |
| Population and setting | discussed | 14 | 8 |
| The comparison | discussed | 8 | 6 |
| Safety and tolerability | discussed | 13 | 9 |
| Design and conduct | discussed | 22 | 11 |
| Dynamic genomic response, assay comparability and monitoring simplicity | discussed | 15 | 9 |
| Clinical readiness and selective implementation | discussed | 17 | 8 |
| Addition versus substitution and the rationale from earlier studies | discussed | 14 | 11 |
| Duration, persistence, overall survival and cumulative treatment burden | discussed | 11 | 1 |
| ctDNA-guided sparing and options for inadequate responders | discussed | 8 | 2 |
| Patient priorities, quality of life and local treatment | discussed | 7 | 2 |
| Research engagement, expansion and anticipated evidence | discussed | 14 | 10 |
| Publication-status dispute and allegations about transparency and harm | discussed | 2 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 31 | 19 |
| LinkedIn posts | 8 | 6 |
| Bluesky threads | 2 | 2 |
| X videos | 2 | 2 |
| Podcasts | 1 | 1 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2022-03-25 to 2026-08-18
- Cited window: 2022-04-22 to 2026-08-18
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
- Registry: NCT05296746 (https://clinicaltrials.gov/study/NCT05296746)
- Study IDs: SOLTI-1911 · BIG-21-02 (BIG)
- Sponsor: SOLTI Breast Cancer Research Group
- Collaborators: Novartis, UNICANCER
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 1,100 (estimated)
- Start: 2022-05-03 (actual)
- Primary completion: 2029-10-01 (estimated)
- Primary endpoint: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort) (Until recurrence (if it happens) for a maximum of 7.5 years of follow-up)
- Intervention: Ribociclib (neoadjuvant) (drug)
- Intervention: Chemotherapy (adjuvant) (drug)
- Intervention: Ribociclib (adjuvant) (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 54 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not representative of all HCP discussion. Identifier-focused searches may miss unnamed references or wording variants, and several passages have not been fully assessed for clinician views.
- Institutional relays, reposts, repeated wording and accounts from people described as involved in RIBOLARIS do not represent independent confirmations or a count of distinct HCP opinions.
- Long-term RIBOLARIS recurrence and survival outcomes are not reported in the reviewed commentary. The available publication describes rationale and design rather than observed trial outcomes.
- Some named authors' clinical roles or identities are not independently established. Anonymous spoken commentary remains attributed to its source, not to a presumed host or presenter.
- Earlier and later accounts describe different enrollment plans and use differing eligibility or endpoint language. These dated descriptions should not be silently merged.
- No separate trial protocol or exact matching regulatory-label documents were available. Absence of those documents does not establish absence of approval.
- The harmful-intent and data-concealment accusations in one thread are not substantiated by the sources reviewed.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition

Last checked for new commentary 2026-10-30. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (139 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (18 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ribolaris-nct05296746
- Agents: POST https://www.erudio.com/api/orders with {"report": "ribolaris-nct05296746", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=ribolaris-05296746

## Cite

Erudio Health. RIBOLARIS (NCT05296746): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/ribolaris-nct05296746

## Machine access

- JSON: https://www.erudio.com/reports/ribolaris-nct05296746.json
- Markdown: https://www.erudio.com/reports/ribolaris-nct05296746.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "ribolaris-05296746"}`